Striatal Hand Deformities: Manifestations, Diagnosis, and Treatment Perspectives

Authors: Avril M. Stulginski, David J. Donehue, Mikhail Pakvasa, Nicolás Phielipp, Eric D. Wang

Abstract

Background:

Striatal hand deformity is a dystonic postural abnormality often observed in patients with Parkinson disease. It is infrequently discussed and often misdiagnosed. The presentation can be confused as a rheumatologic or osteoarthritic condition, delaying appropriate management. This scoping review assessed the existing literature on striatal hand deformities, including study characteristics, treatment modalities, and reported outcomes.

Methods:

Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews guidelines, a comprehensive search was performed across PubMed, Cochrane, Scopus, Google Scholar, Web of Science, and OpenAlex using terms related to “hand deformities,” “neostriatum,” and “striatal hand.” Eligible studies discussed striatal hand deformities; non-peer-reviewed works, abstracts, and opinion pieces were excluded. Extracted data included study design, intervention type, and treatment outcomes. Due to heterogeneity, a narrative synthesis was conducted.

Results:

Thirty-six studies met inclusion 19 case reports, 8 reviews, 6 observational studies, and 3 textbook chapters. Botulinum toxin and levodopa were the most frequently discussed treatments (8 studies each), with mixed outcomes. Surgical approaches and subthalamic nucleus deep brain stimulation were described in a few studies, showing variable results. Nonpharmacologic strategies such as physiotherapy appeared in 9 studies, with limited benefit. Six studies reported minimal or no improvement across interventions.

Conclusions:

This review highlights limited evidence, particularly in hand surgery, on diagnosing and managing striatal hand deformities. Pharmacologic treatments such as botulinum toxin showed inconsistent outcomes, and nonpharmacologic strategies were underexplored. Systematic studies to establish evidence-based diagnostic and treatment protocols are lacking.

INTRODUCTION

Striatal hand is classically seen in Parkinson disease (PD) patients, where the hands and fingers assume an abnormal posture and tone. The classic presentation of striatal hand deformity involves the hand in the intrinsic-plus position with flexion of the metacarpophalangeal (MCP) joints, extension of the interphalangeal (IP) joints, and ulnar deviation of the fingers. The hand can be mistaken for a rheumatoid “intrinsic plus” swan-neck position with ulnar drift and, frequently, a Z-deformity. The striatal hand pattern of deformity was first described by Charcot and Purves-Stewart, who identified a characteristic pattern of postural deformities in patients with PD.^1^ The deformity has also been described in non-PD patients with lesions to the basal ganglia such as anoxic-ischemic encephalopathy and drug-induced parkonsonism. The term “striatal hand” itself stems from early theories suggesting that the deformity was caused by lesions in the striatum, a key structure within the basal ganglia. The basal ganglia includes several nuclei such as the caudate, putamen, globus pallidus interna and externa, and the subthalamic nucleus, all of which play crucial roles in modulating movement and are affected in PD.^2,3^ However, this hypothesis is not fully supported by current literature, and the precise pathogenesis of this deformity remains unclear.^4^

To the uninformed hand surgeon, a striatal hand contracture can be evaluated in much the same way as a dystonic intrinsic-plus contracture. However, not all components are present, and there may be concurrent development of either a boutonniere deformity, with flexion of the proximal interphalangeal joint and extension of the distal interphalangeal joint, or a swan-neck deformity, with flexion of the distal interphalangeal joint and extension of the proximal interphalangeal joint. In the early stages of PD, mild-to-moderate flexion of the MCP joints is often observed.^5^ Approximately 10% of patients with untreated, advanced PD exhibit a striatal hand deformity, with a higher prevalence reported in early-onset cases.^6^ The actual prevalence may be higher, as striatal hand is frequently mistaken for similar deformities seen in rheumatologic hand conditions.^7^ Available reports suggest that striatal hand deformity often begins with mild dystonic posturing that may precede or accompany early motor features of PD, whereas fixed contractures typically emerge later in the disease course after prolonged intrinsic muscle overactivity.^7–9^

Striatal hand is classified into 4 stages according to Wijemanne and Jankovic^10^ (Table 1). Stage 1 is marked by subtle deviation of the MCP joints. As the condition progresses to stage 2, extension of the IP joints occurs, possibly accompanied by a Z-thumb deformity. Stage 3 involves moderate flexion of the MCP joints, swan-neck or boutonniere deformities, and ulnar deviation of the fingers. Stage 4 is the most severe, characterized by advanced deformities with subluxation and contractures (Fig. 1). This differs from rheumatoid arthritis, where both hands are usually involved symmetrically at onset, and there is radiographic evidence of joint involvement. In contrast, striatal hand begins unilaterally, often mirroring the side of onset of other parkinsonian features, and does not show radiographic evidence of joint involvement until more advanced stages.^7^

With such a complex and nuanced presentation, it becomes critical to recognize the key distinguishing features of striatal hand to avoid misdiagnosis. Furthermore, understanding its underlying pathophysiology and progression can guide treatment decisions. In this article, we review the existing literature on the striatal hand deformity and treatment options.

METHODS

Search Strategy

A comprehensive literature search was conducted across multiple PubMed, Cochrane Central, Scopus, Google Scholar, Web of Science, and OpenAlex. This scoping review was designed and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews guidelines (Fig. 2).^11^ The search strategy was developed in conjunction with a librarian, and terms included variations of “hand deformities,” “neostriatum,” “striatal hand deformity,” and “striatal hand deformities” to capture relevant studies on striatal hand deformities. Boolean operators and wildcards were tailored to each database to maximize the sensitivity of the search. A total of 168 references were 49 from OpenAlex, 34 from Scopus, 22 from PubMed, 48 from Google Scholar, and 15 from Web of Science, with Cochrane Central yielding no relevant results (Table 2).

Study Selection

The titles and abstracts of all retrieved records were screened for relevance by 2 authors (A.M.S. and D.D.). Studies were included if they focused on striatal hand deformities or relevant clinical management approaches. Exclusion criteria included non-peer-reviewed literature, conference abstracts, and studies unrelated to striatal deformities. After initial screening, 84 duplicate references were removed by automation, resulting in 84 unique records. Among these, 50 studies were sought for full-text retrieval, with 36 studies meeting the inclusion criteria following a thorough assessment (Fig. 2).

Data Extraction

Data extraction was performed using a standardized table format to capture essential study characteristics, including study type (eg, case report, observational, review, textbook), primary outcomes, and any treatments discussed. The extracted data also noted whether studies showed improvement or no improvement following treatment, and specific interventions were recorded. Improvement was defined as any reported functional, symptomatic, or cosmetic benefit, as described by the original authors. Because the included studies did not use standardized outcome measures, the term “improvement” reflects heterogenous, study-specific definitions unless otherwise specified.

RESULTS

Of the 36 studies included in this scoping review there were 19 case reports, 8 reviews, 6 observational studies, and 3 textbook excerpts (Fig. 3). Each study was analyzed to determine the discussion of treatment approaches and outcomes related to striatal hand deformities, with particular attention to both pharmacologic and nonpharmacologic interventions. The treatment strategies varied widely, with 8 studies discussing the use of botulinum toxin for managing dystonic posturing associated with striatal hand. Only 3 of these studies reported any improvement, and two of these drew from the same cohort of patients with “dystonic clenched fist,” a deformity defined by index finger extension, flexion of the third to fifth MCP joints, and thumb adduction, rather than a true striatal hand presentation.^12^ In that study, improvement was defined as reduced pain or the ability to perform crude grasping movements and was seen in 5 of 10 patients. The remaining study described subjective benefit without quantifiable data. No study provided clear evidence of consistent or meaningful improvement in confirmed striatal hand deformity. Levodopa and other PD medications were discussed in 8 studies, primarily for their potential effect on associated deformities in parkinsonian syndromes.

Two studies mentioned possible neurosurgical interventions for correcting striatal hand, both referencing a 1963 article by Gortvai that described stereotactic lesions to the ventrolateral nucleus of the thalamus.^4,13,14^ A third study described a PD-related claw hand deformity, which is mechanistically distinct from striatal hand; the patient exhibited MCP hyperextension with PIP flexion rather than an intrinsic-plus posture. Although not a striatal hand, standard hand surgery procedures, including Z-lengthening, Bunnell transfer, capsulotomies, improved arc and range of motion, and the authors noted that similar tendon-balancing principles may be relevant to other PD-related dystonic deformities.^15^ Subthalamic nucleus deep brain stimulation (DBS) was discussed in 2 studies, one of which reported a reduction in striatal hand severity from a rating of 4 to 1 following successful treatment.^13,16^ A third study reported a patient who had undergone DBS for her PD with no improvement to her striatal hand deformity.^17^

Additionally, 13 studies explored other treatment options, including careful titration of PD medications, transcranial magnetic stimulation, custom orthotics, ulnar nerve blocking, and corticosteroid therapy. Outcomes varied across the studies, with 6 studies explicitly reporting minimal to no improvement with the investigated PD treatment medical modalities, particularly with levodopa and other drugs.^16,18–22^ Only 1 case report described noticeable improvement with levodopa therapy, although the details of this improvement were not quantified or qualitatively described.^23^ One case report described the use of custom splints, chiropractic manipulation, and transcranial magnetic stimulation of the motor cortex, with noted improvements in hand deformity based on joint motion and angular measurements in the affected hand.^24^

Physiotherapy and rehabilitation-focused interventions, such as stretching and strengthening exercises, were mentioned in 9 studies; however, only 2 case reports detailed specific therapy interventions.^9,25^ One reported minimal improvement, whereas the other noted no improvement. Although some evidence suggested potential functional gains from dynamic splinting, physiotherapy with finger and wrist flexor stretching, and chiropractic rehabilitation therapies, these data were limited and inconclusive.^15,24^ Only 1 case report documented joint stability improvement following the use of a custom orthosis.^24^

The 3 textbooks reviewed provided general overviews of striatal hand but did not include detailed accounts of treatment efficacy.^26–28^ A breakdown of the number of studies discussing each treatment option is provided in Figure 4.

DISCUSSION

Striatal hand deformities can have progressively debilitating effects, especially when unrecognized. This scoping review highlighted the insufficient body of literature available to provide strong, generalizable recommendations for the management of these deformities, particularly concerning surgical interventions. Improved physician education on differentiating striatal hand deformities from other conditions is essential to reduce overall patient morbidity.^3^ Given the heterogeneity of study designs, outcome measures, and treatment strategies across the included studies, the key concepts related to diagnosis, disease progression, and management of striatal hand deformity are summarized in Table 3.

When examining treatments in relation to disease stage, the literature rarely provided consistent stratification. Based on available reports, interventions can be broadly grouped as shown in Table 2. Early-stage dystonic posturing (stage I–II) was occasionally responsive to botulinum toxin, nerve blocks, or adjustments in dopaminergic therapy. In contrast, once fixed deformities developed (stage III–IV), these strategies were ineffective, and only isolated surgical case reports described partial correction through tendon lengthening, capsulotomies, or tendon transfers. Reports of dramatic improvement from stage IV to stage I following DBS likely reflect staging inconsistency rather than true reversal of fixed deformities; indeed, the original authors conceded that DBS may have been initiated before joint contracture had fully developed. Together, these findings underscore the critical role of early identification of striatal hand deformity and dystonic posturing, which may serve as warning signs for progression to a fixed contracture.

This review suggested that botulinum toxin injection therapies targeting intrinsic hand muscles may not be effective in significantly reducing symptom burden. Botulinum toxin injections, commonly used for dystonia, appear less beneficial for striatal hand deformities due to the distinct underlying mechanisms.^29,30^ Mechanistically, botulinum toxin inhibits cholinergic neurotransmission by reducing acetylcholine release at the neuromuscular junction, resulting in muscle paralysis. In dystonia, which involves involuntary muscle contractions leading to abnormal posturing or repetitive movements, botulinum toxin induces chemodenervation to reduce hyperactivity and improve function.^31^ Based on this principle, it has been proposed as a treatment for the abnormal posturing seen in striatal hand. However, the evidence of efficacy is inconsistent, with some studies reporting benefits,^3,32^ whereas others showed no improvement.^9,20,33^

A related hypothesis suggests that interventions blocking the excitation of intrinsic hand muscles may be an effective treatment for striatal hand deformities. This conclusion was based on a single article from 1963, which reported improvement in a PD-related deformity before the adoption of the term “striatal hand,” following an ulnar nerve block with local anesthetic.^14^ The theoretical basis overlaps with botulinum toxin therapy, as both approaches aim to reduce intrinsic muscle hyperexcitability by limiting efferent activity. However, because striatal hand deformity is thought to progress from dystonic posturing to a more contracture-like state, relieving intrinsic hyperexcitability through botulinum toxin or nerve blockade may not be sufficient.^34^

A related study from 2001 examined a hand deformity termed “dystonic clenched fist,” which appears to be very similar to what is now recognized as striatal hand deformity. The findings demonstrated a dose-dependent improvement in pain and functionality with botulinum toxin injections. However, the authors noted that the absence of electromyography activity at rest, which likely indicates established contractures, was associated with a poor response to treatment.^12^ This finding supports the idea that botulinum toxin is effective for dystonic posturing but not for fixed contractures, and that electromyography may be useful is determining the severity of disease. Notably, no study included in this scoping review further evaluated or explored the mechanism of ulnar nerve block for striatal hand deformities.

A key theme throughout this review is the importance of early recognition and management of striatal hand deformities. As discussed, treatments such as nerve blocks and botulinum toxin are more likely to be effective before a contracture develops. Similarly, although anti-parkinsonian medications are generally ineffective for treating striatal hand deformities, this review identified a case report suggesting that early initiation of these medications may provide some benefit. Additionally, a case series of seven patients found that dyskinesias and dystonic posturing preceded the development of fixed contractures by 1–7 years and by several months, respectively. In these cases, both botulinum toxin and adjustments to drug therapy were ineffective in treating the deformity.^9^ From the evidence reviewed in this article and from the characterization of clinical progression of PD, it is clear that the full development of the striatal hand is a feature more commonly seen in untreated PD. In this sense, the side of the body with increased rigidity is the one that develops posturing in flexion of the upper limb with the striatal hand. It is also expected that this is the side of the body with worse resting tremor.^1^ These clinical features also help in the clinical diagnosis of parkinsonian syndromes in general, in addition to their more characteristic finding, which is bradykinesia.^28^

In sum, 3 theoretical schools of treatment option exist—the first targets the potentiation of neurotransmitter effects using systemic drugs or brain stimulation. The second group of techniques works on their targets by causing flaccid paralysis through chemical denervation thus blocking presynaptic acetylcholine release. The third class of techniques, and by far the least well-represented in the literature, uses an understanding of hand anatomy and balance between the opposing forces of the extensor mechanism to surgically correct the deformity. Additionally, there are adjuncts described such as physical therapy and splinting, although these do not address the underlying pathology. It should be emphasized that, aside from dopaminergic pharmacotherapy and deep brain stimulation—both of which are well-established, guideline-supported treatments for global motor symptom control in PD—no intervention has robust, indication-specific evidence for striatal hand deformity. All focal, striatal hand–directed approaches we discuss, including botulinum toxin injection, splinting and hand therapy, corticosteroid injection, soft-tissue or bony surgery, and noninvasive neuromodulation with transcranial magnetic stimulation, are based on low-level or extrapolated evidence and are therefore best regarded as empiric or experimental in this specific context. In particular, transcranial magnetic stimulation is not currently an approved or guideline-supported therapy for motor symptoms of PD and remains investigational, with no data specific to striatal hand deformity.

Future research on striatal hand deformity should address several gaps. First, establishing diagnostic criteria would improve consistency in diagnosis and classification, as well as facilitate more reliable comparisons of treatment outcomes.^10^ Clear diagnostic criteria would reduce ambiguity, making it easier to identify and study the condition in the literature.

Second, there is a notable lack of surgical literature on the correction of striatal hand deformities. Hand surgeons who treat striatal hand deformities should publish case reports and outcomes to build a body of evidence on surgical management. There seems to be a consensus that medical treatment, including functional neurosurgery and DBS, as well as denervation (both chemical and surgical) seem to work only on the early stages of the striatal hand contracture, and that later stages are only amenable to surgical release of the contracture. However, in hand surgery literature, the term “striatal hand” is not common parlance. Hand surgeons, with their advanced understanding of anatomy and biomechanics, and understanding of the treatment of hand deformities related to spastic paresis, cerebral palsy, and dystonia are uniquely well trained to diagnose and manage these contractures. This would require hand surgeons to move beyond disciplinary terminology differences and be willing to take on these difficult and comorbid patients. Conversely, neurosurgeons and neurologists should critically assess their outcomes with pharmaceuticals, botulinum toxin, and DBS and consider early collaboration with hand surgeons who understand the secondary imbalance within hand anatomy and biomechanics.

Finally, further research into the underlying mechanisms driving striatal hand deformity is needed. Developing a comprehensive model, potentially leveraging existing parkinsonian models in nonhuman primates, could provide valuable insights, as these models have demonstrated similar symptoms to those seen in humans, including dystonia and chorea.^35^ Ultimately, hand surgeons may play a crucial role in the early detection of PD when patients present with striatal hand deformities, even before an official PD diagnosis.

As a scoping review this study contains inherent limitations including the possibility that the search terms utilized in the listed search engines may not have yielded all possible existing literature on the topic. The authors utilized the expertise of librarians, and a robust search query to reduce this risk. By nature of the utilized methodology, bias may be introduced through author interpretation of study results; however, this is intrinsic to normal scientific interpretation, and results were agreed upon by multiple authors along with exclusion of non-peer-reviewed publications. Last, given the lack of expert consensus on the topic, the inconsistently measured outcomes limiting cross-study comparison, and clear inadequacy of the preexisting literature in addressing striatal hand deformities, we are unable to make strong management recommendations, which highlights the largest limitation of the study.

CONCLUSIONS

Although a PD patient with a dystonic hand contracture is not commonly thought of as an indication to involve a hand surgeon, the hand surgery community should be aware of the striatal hand. Techniques that can be applied to cerebral palsy, spastic hemiplegia, and dystonic claw hands can be applied to the striatal hand as well.

DISCLOSURE

The authors have no financial interest to declare in relation to the content of this article.

ACKNOWLEDGEMENT

The authors would like to acknowledge Linda SukLing Murphy from the UC Irvine Libraries for her assistance in developing a search strategy for this work.